Valuation: Plus Therapeutics, Inc.

Market Cap 26.29M 23.13M 21.48M 19.76M 37.05M 2.55B 37.72M 257M 100M 1.24B 98.71M 96.58M 4.31B P/E 2026 *
-0.97x
P/E 2027 * -1.59x
Enterprise Value 26.29M 23.13M 21.48M 19.76M 37.05M 2.55B 37.72M 257M 100M 1.24B 98.71M 96.58M 4.31B EV / Sales 2026 *
4.18x
EV / Sales 2027 * 1.37x
Free-Float
98.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plus Therapeutics, Inc.

1 day-1.05%
1 week-3.08%
Current month-13.50%
1 month-7.35%
3 months-48.08%
6 months-44.23%
Current year-70.49%
1 week 3.58
Extreme 3.58
4.08
1 month 3.58
Extreme 3.58
4.51
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
870
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Fiscal year

Director

1,844 0.0269%
1/7/26 Fiscal year

Director

1,844 0.0269%
1/7/26 Fiscal year

Director

1,844 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
-1.05%-3.08%-69.14%-92.90% 26.29M
+1.08%-6.74%-2.31%+10.45% 46.06B
+3.13%+5.34%+402.93%+627.64% 38.91B
+2.14%+2.95%+10.83%+67.37% 35.57B
+4.43%-1.51%+6.73%-9.13% 33.13B
+1.23%-1.99%-0.05%+30.76% 26.42B
+0.29%-2.75% - - 16.61B
+14.71%+12.62%+38.50%+145.33% 15.08B
-6.32%-4.59%+4.36%+8.22% 14.08B
+1.82%+0.19%+1.45%-29.80% 12.81B
Average +2.23%-2.55%+43.70%+84.21% 23.87B
Weighted average by Cap. +2.60%-2.47%+75.82%+133.88%

Financials

2026 *2027 *
Net sales 6.3M 5.54M 5.14M 4.73M 8.87M 610M 9.03M 61.51M 23.99M 297M 23.63M 23.12M 1.03B 19.14M 16.83M 15.64M 14.38M 26.97M 1.85B 27.46M 187M 72.94M 904M 71.86M 70.3M 3.14B
Net income -26.8M -23.57M -21.9M -20.14M -37.77M -2.6B -38.44M -262M -102M -1.27B -101M -98.44M -4.39B -18.45M -16.23M -15.08M -13.87M -26.01M -1.79B -26.47M -180M -70.33M -872M -69.28M -67.78M -3.02B
Net Debt - -
Logo Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Employees
28
Date Price Change Volume
24/07/26 US$3.780 -1.05% 62,484
22/07/26 US$3.820 -2.55% 57,632
21/07/26 US$3.920 +2.35% 75,574
20/07/26 US$3.830 +2.41% 70,625
17/07/26 US$3.740 -4.10% 215,179
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.820USD
Average target price
36.00USD
Spread / Average Target
+842.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSTV Stock